Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Daniel Habermehl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-7316-6422; OpenAlex author ID A5022748731. Sources: OpenAlex.

Their work

Papers
17 (first author 10, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 6 papers · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 17

  1. Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outcome. Co-author DOI 10.3389/fonc.2026.1710943↗
  2. Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both? First author DOI 10.1186/s13014-017-0945-2↗
  3. Changes in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-Ho… Co-author DOI 10.1177/1533034615577515↗
  4. Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific α/β-Values for Patients with Non-Resectable Pancreatic Cancer. Last author DOI 10.1371/journal.pone.0164473↗
  5. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-015-0560-3↗
  6. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. First author DOI 10.1186/s13014-015-0538-x↗
  7. Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group. Co-author DOI 10.1186/2047-783x-19-24↗
  8. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. First author DOI 10.1245/s10434-014-3607-8↗
  9. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comp… First author DOI 10.1007/s00066-013-0391-5↗
  10. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. First author DOI 10.1007/s00066-013-0393-3↗
  11. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. First author DOI 10.1093/jrr/rrt052↗
  12. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. First author DOI 10.1186/1471-2407-13-419↗
  13. Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanc… First author DOI 10.1186/1748-717x-8-138↗
  14. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Co-author DOI 10.1186/1748-717x-8-27↗
  15. [Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer]. First author DOI 10.1007/s00066-012-0214-0↗
  16. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-7-28↗
  17. [Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer]. First author DOI 10.1007/s00104-011-2129-1↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephanie Elisabeth Combs · 16 shared papers, 2011–2017 · strength 0.74
  2. Jürgen Debus · 15 shared papers, 2011–2016 · strength 0.64
  3. Ahmed Gawish · 1 shared paper, 2026 · strength 0.26
  4. Fabian Eberle · 1 shared paper, 2026 · strength 0.26
  5. Thomas Held · 1 shared paper, 2026 · strength 0.26
  6. Philipp Lishewski · 1 shared paper, 2026 · strength 0.26
  7. Markus Wolfgang Büchler · 7 shared papers, 2011–2015 · strength 0.26
  8. Jens Werner · 7 shared papers, 2011–2015 · strength 0.26
  9. Constantin Dreher · 4 shared papers, 2013–2017 · strength 0.24
  10. Oliver Jäkel · 4 shared papers, 2013–2017 · strength 0.24
  11. Kerstin Anne Kessel · 6 shared papers, 2012–2016 · strength 0.24
  12. Dirk Jäger · 4 shared papers, 2013–2015 · strength 0.16
  13. Stefan Rieken · 4 shared papers, 2012–2015 · strength 0.15
  14. Patrick Naumann · 2 shared papers, 2013–2014 · strength 0.09
  15. Rami Ateyah El Shafie · 2 shared papers, 2013–2015 · strength 0.09
  16. Christoph Springfeld · 1 shared paper, 2015 · strength 0.05
  17. Andrea Mairani · 1 shared paper, 2013 · strength 0.03
  18. Jürgen Weitz · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.